Emergent BioSolutions

Global MCM Demand And Political Risks Will Shape Outlook

AnalystConsensusTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

26 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$13.50

34.5% undervalued

15 Aug

US$8.84

-26.9%

8.3%

Author's Valuation

US$13.5

34.5% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25

AnalystConsensusTarget Fair Value

US$13.5

34.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-4.62%

Biotech revenue growth rate

13.11%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.93%

Calculation

US$104.06m

Earnings '28

9.05x

PE Ratio '28

US$942.16m

Market Cap '28

US$942.16m

Market Cap '28

54.71m

No. shares '28

US$17.22

Share Price '28

US$17.22 Share Price '28

Discounted to 2025 @ 8.93% p.a.

US$13.33

Fair Value '25